T/C Gynecologic Pathology
Reading File
Asking for Preferences
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I have enough content from the first read to compile a comprehensive overview. Let me now synthesize everything into a well-organized reference.
Gynecologic Pathology — High-Yield Overview
Primary source: Robbins & Kumar Basic Pathology, 10th ed. | Robbins, Cotran & Kumar Pathologic Basis of Disease
1. VULVA
Non-Neoplastic Disorders
| Condition | Key Features |
|---|---|
| Lichen sclerosus | Thinning of epidermis, white plaques ("leukoplakia"); parchment-like skin; seen in postmenopausal women; small risk of SCC |
| Squamous cell hyperplasia | Thickened epithelium + dermal inflammatory infiltrate; must biopsy to rule out carcinoma |
Both lichen sclerosus and squamous cell hyperplasia must be biopsied to exclude squamous cell carcinoma.
Vulvar Tumors
- HPV-related vulvar SCC — poorly differentiated, often multifocal; arises from vulvar intraepithelial neoplasia (VIN); HPV 16/18
- Non-HPV vulvar SCC — older women; well differentiated, unifocal; preceded by differentiated VIN (dVIN) associated with lichen sclerosus
- Vulvar Paget disease — red, scaly plaque from intraepidermal proliferation of Paget cells; unlike Paget of the nipple, usually no underlying carcinoma
2. VAGINA
- Vaginal adenosis — columnar epithelium in vagina (normally squamous); associated with in utero DES exposure
- Clear cell adenocarcinoma — linked to DES exposure; arises from vaginal adenosis
- Embryonal rhabdomyosarcoma (sarcoma botryoides) — polypoid, grape-like vaginal mass in girls <5 years; rhabdomyoblasts ("strap cells")
3. CERVIX
Cervical Neoplasia
Risk Factors (all related to HPV exposure):
- Early age at first intercourse
- Multiple sexual partners
- Cigarette smoking
- Immunodeficiency (HIV)
HPV Pathogenesis:
- Nearly all cervical carcinomas caused by HPV — especially high-risk types 16, 18, 31, 33
- HPV E6 → inactivates p53 (→ ↑proliferation, suppressed apoptosis)
- HPV E7 → inactivates RB (→ ↑cell cycle progression)
- High-risk HPV integrates into host genome → ↑↑ E6/E7 expression → progression to carcinoma
Precursor Lesions (SIL):
| Grade | Old Terminology | Features |
|---|---|---|
| LSIL | CIN 1 | Lower 1/3 epithelial dysplasia; koilocytosis |
| HSIL | CIN 2/3 | 2/3 to full-thickness dysplasia; high malignant potential |
- Transformation zone (squamocolumnar junction) = the most common site of origin
- Pap smear remains the gold standard screening tool; HPV co-testing now used alongside
- HPV vaccine (Gardasil) prevents infection from types 16, 18, 6, 11 (and extended strains in 9-valent)
Invasive Cervical Carcinoma:
- Squamous cell carcinoma — ~80%; arises at transformation zone
- Adenocarcinoma — ~15–20%; arises from endocervical glands; HPV 18 most common
- Spreads by direct extension and lymphatics
4. UTERUS (CORPUS)
Non-Neoplastic Endometrial Disorders
| Condition | Definition | Clinical |
|---|---|---|
| Adenomyosis | Endometrial glands/stroma within the myometrium | Uterine enlargement, dysmenorrhea, menorrhagia |
| Endometriosis | Endometrial glands/stroma outside the uterus | Dysmenorrhea, pelvic pain, infertility; cyclic bleeding; ↑ COX-2 |
Endometriosis sites: Ovaries (chocolate cysts/endometriomas) > pelvic peritoneum > rectovaginal septum > Pouch of Douglas
Endometrial Hyperplasia
Cause: Unopposed estrogen (endogenous or exogenous)
Risk Factors:
- Anovulatory cycles
- Polycystic ovarian syndrome (PCOS)
- Estrogen-secreting ovarian tumors
- Obesity (peripheral aromatization of androgens)
- Estrogen therapy without progestin
Classification (based on cytologic atypia):
| Type | Risk of Progression to Carcinoma |
|---|---|
| Without atypia | ~1–3% |
| With atypia (EIN — endometrial intraepithelial neoplasia) | ~25–30% |
Endometrial Carcinoma
Two major types:
| Feature | Type I (Endometrioid) | Type II (Serous) |
|---|---|---|
| Precursor | Endometrial hyperplasia/EIN | Endometrial intraepithelial carcinoma (EIC) |
| Estrogen-related | Yes | No |
| Grade | Low | High |
| Mutation | PTEN, KRAS, MLH1, β-catenin, microsatellite instability | TP53, HER2/neu |
| Prognosis | Better | Worse |
| Background endometrium | Hyperplastic | Atrophic |
- Most common gynecologic malignancy in developed nations
- Presents with postmenopausal vaginal bleeding
- Staging is surgical (FIGO)
Uterine Mesenchymal Tumors
| Tumor | Features |
|---|---|
| Leiomyoma (fibroid) | Most common uterine tumor overall; benign smooth muscle; whorled, well-circumscribed; estrogen-sensitive; multiple in 75%; rarely malignant transformation |
| Leiomyosarcoma | Malignant smooth muscle; ≥10 mitoses/10 HPF + necrosis + atypia; de novo (NOT from leiomyoma) |
5. FALLOPIAN TUBE
- Salpingitis — most commonly gonococcal or chlamydial (PID); can lead to hydrosalpinx, pyosalpinx, tubo-ovarian abscess
- Ectopic pregnancy — most common site = ampulla; presents with pain, amenorrhea, ↑βhCG; can rupture → hemoperitoneum (surgical emergency)
- Carcinoma — rare; increasingly recognized as the site of origin for "ovarian" high-grade serous carcinoma (arising from STIC — serous tubal intraepithelial carcinoma)
6. OVARY
Classification of Ovarian Tumors
| Origin | Tumor Type | % of Ovarian Tumors |
|---|---|---|
| Surface epithelium | Serous, mucinous, endometrioid, clear cell, Brenner | ~65–70% |
| Germ cells | Teratoma, dysgerminoma, yolk sac tumor, choriocarcinoma | ~15–20% |
| Sex cord-stromal | Granulosa cell, Sertoli-Leydig, fibroma/thecoma | ~5–10% |
| Metastatic | Krukenberg tumor | ~5% |
Surface Epithelial Tumors
| Tumor | Key Features |
|---|---|
| Serous cystadenoma | Most common benign ovarian tumor; psammoma bodies in malignant variant |
| Serous cystadenocarcinoma | Most common ovarian malignancy; bilateral ~66%; psammoma bodies; TP53, BRCA1/2 mutations |
| Mucinous tumors | Large, multilocular cysts; may be bilateral if Pseudomyxoma peritonei (actually from appendix) |
| Endometrioid carcinoma | Associated with endometriosis; PTEN mutation |
| Clear cell carcinoma | Associated with endometriosis; worst prognosis among epithelial types |
| Brenner tumor | Usually benign; "coffee bean" nuclei; resembles transitional epithelium |
High-grade serous carcinoma (HGSC):
- TP53 mutation (near universal)
- BRCA1/BRCA2 mutations → ↑ homologous recombination deficiency → responds to PARP inhibitors
- Likely originates from STIC in fallopian tube fimbria
- Spreads by exfoliation → peritoneal seeding → ascites
Germ Cell Tumors
| Tumor | Age | Key Features |
|---|---|---|
| Mature cystic teratoma (dermoid cyst) | Reproductive age | Most common ovarian germ cell tumor; contains all 3 germ layers (teeth, hair, sebum); benign; 1–2% malignant transformation to SCC |
| Dysgerminoma | Adolescents/young adults | Equivalent to testicular seminoma; bilateral 10–15%; radiosensitive; ↑LDH; associated with gonadal dysgenesis |
| Yolk sac tumor (endodermal sinus tumor) | Children/young women | ↑↑ AFP; Schiller-Duval bodies (glomeruloid structures); aggressive |
| Choriocarcinoma (gestational vs. non-gestational) | Reproductive age | ↑↑ βhCG; hemorrhagic; highly malignant; responds to chemotherapy |
| Immature teratoma | Young women | Contains immature neuroectodermal elements; graded I–III |
| Embryonal carcinoma | Young women | ↑AFP + ↑βhCG |
Sex Cord-Stromal Tumors
| Tumor | Hormone | Manifestation |
|---|---|---|
| Granulosa cell tumor | Estrogen | Precocious puberty (girls); endometrial hyperplasia/carcinoma; Call-Exner bodies (rosettes of cells around eosinophilic material); coffee bean nuclei; FOXL2 mutation |
| Thecoma/fibroma | Estrogen/none | Meigs syndrome = fibroma + ascites + right pleural effusion |
| Sertoli-Leydig cell tumor | Androgens | Virilization (hirsutism, clitoromegaly, voice deepening) |
Metastatic Tumors to Ovary
- Krukenberg tumor — bilateral metastases to ovaries, classically from gastric carcinoma; signet-ring cells in a cellular stroma; also from colorectal, breast, appendix primaries
7. GESTATIONAL TROPHOBLASTIC DISEASE (GTD)
| Condition | Karyotype | Features | βhCG |
|---|---|---|---|
| Complete hydatidiform mole | 46,XX (paternal) | All villi hydropic; no fetus; 2–3% → choriocarcinoma | ↑↑↑ |
| Partial hydatidiform mole | 69,XXX or 69,XXY (triploid) | Some villi normal; fetus may be present; <1% malignant | ↑ |
| Invasive mole | — | Invades myometrium; rarely metastasizes; responds to chemo | ↑↑ |
| Choriocarcinoma | — | No villi; cytotrophoblast + syncytiotrophoblast; highly malignant; hematogenous spread; highly chemo-sensitive (MTX) | ↑↑↑ |
| Placental site trophoblastic tumor (PSTT) | — | Intermediate trophoblasts; ↑hPL; resistant to MTX; treated surgically | Low-moderate |
Mole management: Uterine evacuation → serial βhCG monitoring → if plateau or rise → chemotherapy
Summary: High-Yield Associations
| Finding | Diagnosis |
|---|---|
| Koilocytes on Pap | HPV infection (LSIL) |
| Psammoma bodies | Serous cystadenocarcinoma of ovary, papillary thyroid CA, meningioma |
| Call-Exner bodies | Granulosa cell tumor |
| Schiller-Duval bodies | Yolk sac tumor (↑AFP) |
| Signet-ring cells, bilateral ovarian mets | Krukenberg tumor (gastric primary) |
| Meigs syndrome | Ovarian fibroma |
| "Coffee bean" nuclei | Granulosa cell tumor (also Brenner) |
| Chocolate cysts | Endometriosis (ovarian endometriomas) |
| Grape-like vaginal mass in infant | Sarcoma botryoides |
| DES exposure in utero | Clear cell adenocarcinoma of vagina |
| BRCA1/2 + TP53 | High-grade serous ovarian carcinoma |
| FOXL2 mutation | Granulosa cell tumor |
| ↑AFP | Yolk sac tumor, hepatocellular carcinoma |
| 46,XX (all paternal) | Complete hydatidiform mole |
| Triploid (69,XXX) | Partial hydatidiform mole |
| Postmenopausal bleeding | Endometrial carcinoma (until proven otherwise) |
Sources: Robbins & Kumar Basic Pathology (9780323790185); Robbins, Cotran & Kumar Pathologic Basis of Disease (9780443264528); Berek & Novak's Gynecology (9781496380357)
This is a shared conversation. Sign in to Orris to start your own chat.